Deciding which biomarkers to include and what technology to use is neither simple nor straight forward. Clinical relevance, reliability, and practicality are of critical importance for biomarker selection.
Using robust genomic sequencing data and molecular testing trends, QIAGEN RWI analyses can identify, prioritize and validate biomarkers of therapeutic response and resistance to optimize your drug development strategy.